Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) Research & Development (2016 - 2025)

Kiora Pharmaceuticals' Research & Development history spans 11 years, with the latest figure at $1.8 million for Q4 2025.

  • For Q4 2025, Research & Development rose 136.98% year-over-year to $1.8 million; the TTM value through Dec 2025 reached $7.1 million, up 140.41%, while the annual FY2025 figure was $10.8 million, 37.47% up from the prior year.
  • Research & Development reached $1.8 million in Q4 2025 per KPRX's latest filing, up from $1.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $2.0 million in Q1 2025 to a low of $189904.0 in Q1 2024.
  • Average Research & Development over 5 years is $1.2 million, with a median of $1.1 million recorded in 2024.
  • Peak YoY movement for Research & Development: plummeted 60.61% in 2022, then surged 936.98% in 2025.
  • A 5-year view of Research & Development shows it stood at $1.0 million in 2021, then soared by 33.0% to $1.3 million in 2022, then dropped by 16.55% to $1.1 million in 2023, then tumbled by 33.47% to $739557.0 in 2024, then skyrocketed by 136.98% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Research & Development are $1.8 million (Q4 2025), $1.7 million (Q3 2025), and $1.7 million (Q2 2025).